• -
  • English
  • Japanese
  • Korean
表紙
市場調查報告書
商品編碼
1065176

全球 API 市場展望（2020-2030 年）

Global Active Pharmaceutical Ingredients Market Outlook 2020-2030
出版日期: | 出版商: Research Nester | 英文 170 Pages | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球原料藥市場預計將從 2020 年的 1850 億美元增長到 2030 年底的約 3300 億美元。預計在預測期間（2021 年至 2030 年），其複合年增長率也將達到 6.08%。市場的主要驅動力是仿製藥批准數量的增加、仿製藥和生物仿製藥需求的增長、醫療成本的增加以及全球慢性病的增加。

從治療用途來看，心血管疾病領域是最大的細分市場，預計到 2030 年底將達到約 700 億美元。按地區劃分，北美是最大的市場，預計到 2030 年底將超過 1250 億美元。

本報告分析了全球原料藥（API）市場的未來前景，預測了市場的基本結構和背景（監管體系、主要市場促進/制約因素等）和市場規模趨勢（從2020年開始）到 2030 年），將匯總並提供按細分市場和地區劃分的詳細趨勢、當前的市場競爭狀況、主要公司的概況等。

目錄

第一章市場的定義

第 2 章假設和首字母縮略詞

第三章調查方法

第 4 章執行摘要：全球 API 市場

第五章市場動態

  • 市場促進因素
  • 市場趨勢

第6章主要市場機會

第 7 章市場增長的主要障礙

第8章監管和標準情況

第九章行業風險分析

第10章藥品原料藥（API）市場價格分析

第11章產業價值鏈分析

第 12 章貿易展望

  • 導入
  • 導出

第 13 章 COVID-19 對 API 市場的影響

第十四章產品功能分析

第十五章競爭定位

第16章競爭結構

  • 市場份額分析（2020 年）
  • 競爭基準
  • 公司簡介
    • Pfizer Inc.
    • GlaxoSmithKline plc
    • Novartis AG
    • Sanofi-aventis Groupe
    • Boehringer Ingelheim International GmbH
    • Aurobindo Pharma
    • Dr. Reddy's Laboratories Ltd.
    • API Corporation
    • Bristol-Myers Squibb Company
    • KATSURA CHEMICAL CO., LTD.

第十七章全球API市場展望

  • 市場規模：基於金額（10億美元）
  • 市場部
    • 按類型
    • 按合成方法
    • 按治療用途
    • 按業務模式
    • 按地區

第18章北美API市場展望

第 19 章歐洲 API 市場展望

第20章亞太API（API）市場展望

第 21 章拉丁美洲 API 市場展望

第 22 章中東/非洲藥物 API (API) 市場展望

目錄

The global active pharmaceutical ingredients (API) market is anticipated to grow with a CAGR of 6.08% over the forecast period, i.e., 2021 - 2030. Factors such as the increasing number of generic drug approvals, followed by the growing demand for generic and biosimilar drugs, and the rising healthcare expenditure are anticipated to drive the growth of the market in the coming years. Moreover, factors such as the rising prevalence of chronic diseases worldwide, which is driving the need amongst the pharmaceutical drug manufacturers to develop advanced medicines to treat these diseases, is also expected to drive the demand for active pharmaceutical ingredients (APIs) in the coming years, and in turn, contribute to the growth of the market. The market is estimated to garner a revenue of near to USD 330 Billion by the end of 2030, up from a revenue of around USD 185 Billion in the year 2020.

The global active pharmaceutical ingredients (API) market is segmented by numerous segments, which include segmentation by type, synthesis type, therapeutic application, business mode, and by region. Based on therapeutic application, the market is segmented into communicable disease, oncology, diabetes, cardiovascular disease, musculoskeletal disorders, respiratory disorders, and other therapeutic applications. The cardiovascular disease segment is anticipated to garner the largest revenue of near to USD 70 Billion by the end of 2030, amongst all the other segments. Moreover, the segment generated a revenue of about USD 40 Billion in the year 2020.

On the basis of regional analysis, the global active pharmaceutical ingredients (API) market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa. The market in North America is anticipated to garner the largest revenue of more than USD 125 Billion by the end of 2030 amongst the markets in all the other regions. Moreover, in the year 2020, the market in the region registered a revenue of around USD 70 Billion.

Some of the prominent industry leaders in the global active pharmaceutical ingredients (API) market that are included in our report are: Pfizer Inc., GlaxoSmithKline plc, Novartis AG, Sanofi-aventis Groupe, Boehringer Ingelheim International GmbH, Aurobindo Pharma, Dr. Reddy's Laboratories Ltd., API Corporation, Bristol-Myers Squibb Company, KATSURA CHEMICAL CO., LTD., and others.

Table of Contents

1. Market Definition

  • 1.1. Definition
  • 1.2. Market Segmentation

2. Assumptions and Acronyms

3. Research Methodology

  • 3.1. Research Process
  • 3.2. Primary Research
  • 3.3. Secondary Research

4. Executive Summary - Global Active Pharmaceutical Ingredients (API) Market

5. Market Dynamics

  • 5.1. Market Drivers
  • 5.2. Market Trends

6. Key Market Opportunities

7. Major Roadblocks for the Market Growth

8. Regulatory and Standards Landscape

9. Industry Risk Analysis

10. Pricing Analysis of Active Pharmaceutical Ingredients (API) Market

11. Industry Value Chain Analysis

12. Trade Outlook

  • 12.1. Import
  • 12.2. Export

13. Impact of COVID-19 on the Active Pharmaceutical Ingredients (API) Market

14. Product Feature Analysis

15. Competitive Positioning

16. Competitive Structure

  • 16.1. Market Share Analysis, 2020
  • 16.2. Competitive Benchmarking
  • 16.3. Company Profiles
    • 16.3.1. Pfizer Inc.
    • 16.3.2. GlaxoSmithKline plc
    • 16.3.3. Novartis AG
    • 16.3.4. Sanofi-aventis Groupe
    • 16.3.5. Boehringer Ingelheim International GmbH
    • 16.3.6. Aurobindo Pharma
    • 16.3.7. Dr. Reddy's Laboratories Ltd.
    • 16.3.8. API Corporation
    • 16.3.9. Bristol-Myers Squibb Company
    • 16.3.10. KATSURA CHEMICAL CO., LTD.

17. Global Active Pharmaceutical Ingredients (API) Market Outlook

  • 17.1. Market by Value (USD Billion)
  • 17.2. Market Segmentation
    • 17.2.1. By Type
      • 17.2.1.1. Generic, 2020-2030F (USD Billion)
      • 17.2.1.2. Innovative, 2020-2030F (USD Billion)
    • 17.2.2. By Synthesis Type
      • 17.2.2.1. Synthetic, 2020-2030F (USD Billion)
      • 17.2.2.2. Biotech, 2020-2030F (USD Billion)
    • 17.2.3. By Therapeutic Application
      • 17.2.3.1. Communicable Diseases, 2020-2030F (USD Billion)
      • 17.2.3.2. Oncology, 2020-2030F (USD Billion)
      • 17.2.3.3. Diabetes, 2020-2030F (USD Billion)
      • 17.2.3.4. Cardiovascular Disease, 2020-2030F (USD Billion)
      • 17.2.3.5. Musculoskeletal Disorders, 2020-2030F (USD Billion)
      • 17.2.3.6. Respiratory Diseases, 2020-2030F (USD Billion)
      • 17.2.3.7. Other Therapeutic Applications, 2020-2030F (USD Billion)
    • 17.2.4. By Business Mode
      • 17.2.4.1. Captive, 2020-2030F (USD Billion)
      • 17.2.4.2. Merchant, 2020-2030F (USD Billion)
    • 17.2.5. By Region
      • 17.2.5.1. North America, 2020-2030F (USD Billion)
      • 17.2.5.2. Europe, 2020-2030F (USD Billion)
      • 17.2.5.3. Asia Pacific, 2020-2030F (USD Billion)
      • 17.2.5.4. Latin America, 2020-2030F (USD Billion)
      • 17.2.5.5. Middle East & Africa, 2020-2030F (USD Billion)

18. North America Active Pharmaceutical Ingredients (API) Market Outlook

  • 18.1. Market by Value (USD Billion)
  • 18.2. Market Segmentation
    • 18.2.1. By Type
      • 18.2.1.1. Generic, 2020-2030F (USD Billion)
      • 18.2.1.2. Innovative, 2020-2030F (USD Billion)
    • 18.2.2. By Synthesis Type
      • 18.2.2.1. Synthetic, 2020-2030F (USD Billion)
      • 18.2.2.2. Biotech, 2020-2030F (USD Billion)
    • 18.2.3. By Therapeutic Application
      • 18.2.3.1. Communicable Diseases, 2020-2030F (USD Billion)
      • 18.2.3.2. Oncology, 2020-2030F (USD Billion)
      • 18.2.3.3. Diabetes, 2020-2030F (USD Billion)
      • 18.2.3.4. Cardiovascular Disease, 2020-2030F (USD Billion)
      • 18.2.3.5. Musculoskeletal Disorders, 2020-2030F (USD Billion)
      • 18.2.3.6. Respiratory Diseases, 2020-2030F (USD Billion)
      • 18.2.3.7. Other Therapeutic Applications, 2020-2030F (USD Billion)
    • 18.2.4. By Business Mode
      • 18.2.4.1. Captive, 2020-2030F (USD Billion)
      • 18.2.4.2. Merchant, 2020-2030F (USD Billion)
    • 18.2.5. By Country
      • 18.2.5.1. United States, 2020-2030F (USD Billion)
      • 18.2.5.2. Canada, 2020-2030F (USD Billion)

19. Europe Active Pharmaceutical Ingredients (API) Market Outlook

  • 19.1. Market by Value (USD Billion)
  • 19.2. Market Segmentation
    • 19.2.1. By Type
    • 19.2.2. By Synthesis Type
    • 19.2.3. By Therapeutic Application
    • 19.2.4. By Business Mode
    • 19.2.5. By Country
      • 19.2.5.1. United Kingdom, 2020-2030F (USD Billion)
      • 19.2.5.2. Germany, 2020-2030F (USD Billion)
      • 19.2.5.3. Italy, 2020-2030F (USD Billion)
      • 19.2.5.4. France, 2020-2030F (USD Billion)
      • 19.2.5.5. Spain, 2020-2030F (USD Billion)
      • 19.2.5.6. Russia, 2020-2030F (USD Billion)
      • 19.2.5.7. Netherlands, 2020-2030F (USD Billion)
      • 19.2.5.8. Rest of Europe, 2020-2030F (USD Billion)

20. Asia Pacific Active Pharmaceutical Ingredients (API) Market Outlook

  • 20.1. Market by Value (USD Billion)
  • 20.2. Market Segmentation
    • 20.2.1. By Type
    • 20.2.2. By Synthesis Type
    • 20.2.3. By Therapeutic Application
    • 20.2.4. By Business Mode
    • 20.2.5. By Country
      • 20.2.5.1. Japan, 2020-2030F (USD Billion)
      • 20.2.5.2. Australia, 2020-2030F (USD Billion)
      • 20.2.5.3. Singapore, 2020-2030F (USD Billion)
      • 20.2.5.4. South Korea, 2020-2030F (USD Billion)
      • 20.2.5.5. India, 2020-2030F (USD Billion)
      • 20.2.5.6. China, 2020-2030F (USD Billion)
      • 20.2.5.7. Rest of Asia Pacific, 2020-2030F (USD Billion)

21. Latin America Active Pharmaceutical Ingredients (API) Market Outlook

  • 21.1. Market by Value (USD Billion)
  • 21.2. Market Segmentation
    • 21.2.1. By Type
    • 21.2.2. By Synthesis Type
    • 21.2.3. By Therapeutic Application
    • 21.2.4. By Business Mode
    • 21.2.5. By Country
      • 21.2.5.1. Brazil, 2020-2030F (USD Billion)
      • 21.2.5.2. Argentina, 2020-2030F (USD Billion)
      • 21.2.5.3. Mexico, 2020-2030F (USD Billion)
      • 21.2.5.4. Rest of Latin America, 2020-2030F (USD Billion)

22. Middle East & Africa Active Pharmaceutical Ingredients (API) Market Outlook

  • 22.1. Market by Value (USD Billion)
  • 22.2. Market Segmentation
    • 22.2.1. By Type
    • 22.2.2. By Synthesis Type
    • 22.2.3. By Therapeutic Application
    • 22.2.4. By Business Mode
    • 22.2.5. By Country
      • 22.2.5.1. GCC, 2020-2030F (USD Billion)
      • 22.2.5.2. Israel, 2020-2030F (USD Billion)
      • 22.2.5.3. South Africa, 2020-2030F (USD Billion)
      • 22.2.5.4. Rest of Middle East & Africa, 2020-2030F (USD Billion)